Comparison

Cagrilintide vs. Eloralintide

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

Cagrilintide

Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.

Eloralintide

Eloralintide selectively activates amylin receptors (preferentially AMY1R) and promotes satiety. The approach targets weight loss via the amylin axis, complementary to or independent of GLP-1 agents.

Evidence base

Highest evidence

Human RCT

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	Cagrilintide	Eloralintide
Germany	Unapproved	Unapproved
DK	Unapproved	—
United States	Unapproved	Unapproved

Full entries

Frequently asked questions

What is the difference between Cagrilintide and Eloralintide?: Cagrilintide is classified as "Metabolic", while Eloralintide is classified as "Metabolic". Cagrilintide: Synthetic long-acting amylin analog being developed in combination with semaglutide (CagriSema). Phase 3 trials for obesity and type 2 diabetes are ongoing. No marketing approval yet. Eloralintide: Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Cagrilintide or Eloralintide?: The highest available evidence level is "Human RCT" for Cagrilintide and "Human RCT" for Eloralintide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Cagrilintide and Eloralintide in Germany and the United States?: Germany: Cagrilintide — Unapproved, Eloralintide — Unapproved. United States: Cagrilintide — Unapproved, Eloralintide — Unapproved. These are factual summaries with source and review date on the individual pages.

Country

Cagrilintide

Eloralintide

Germany

Unapproved

—

United States

Unapproved

Frequently asked questions

What is the difference between Cagrilintide and Eloralintide?

Cagrilintide is classified as "Metabolic", while Eloralintide is classified as "Metabolic". Cagrilintide: Synthetic long-acting amylin analog being developed in combination with semaglutide (CagriSema). Phase 3 trials for obesity and type 2 diabetes are ongoing. No marketing approval yet. Eloralintide: Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Cagrilintide or Eloralintide?

The highest available evidence level is "Human RCT" for Cagrilintide and "Human RCT" for Eloralintide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Cagrilintide and Eloralintide in Germany and the United States?

Germany: Cagrilintide — Unapproved, Eloralintide — Unapproved. United States: Cagrilintide — Unapproved, Eloralintide — Unapproved. These are factual summaries with source and review date on the individual pages.